Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer

OBJECTIVE: Despite the promising efficacy of the novel antibody-drug conjugate trastuzumab deruxtecan in treating Hormone Receptor (HoR)-positive/Human Epidermal Growth Factor Receptor 2 (HER2)-low metastatic breast cancer (MBC), its categorization as a distinct entity remains disputed, as does the...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Shuhui, Gong, Chengcheng, Li, Yi, Xie, Yizhao, Li, Yumeng, Zhao, Yannan, Wang, Biyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595148/
https://www.ncbi.nlm.nih.gov/pubmed/37881502
http://dx.doi.org/10.3389/fendo.2023.1270453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595148/
https://www.ncbi.nlm.nih.gov/pubmed/37881502
http://dx.doi.org/10.3389/fendo.2023.1270453

Ejemplares similares